These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24843740)

  • 81. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
    Yang W; Zhu D; Gan S; Dong X; Su J; Li W; Jiang H; Zhao W; Yao M; Song W; Lu Y; Zhang X; Li H; Wang G; Qiu W; Yuan G; Ma J; Li W; Li Z; Wang X; Zeng J; Yang Z; Liu J; Liang Y; Lu S; Zhang H; Liu H; Liu P; Fan K; Jiang X; Li Y; Su Q; Ning T; Tan H; An Z; Jiang Z; Liu L; Zhou Z; Zhang Q; Li X; Shan Z; Xue Y; Mao H; Shi L; Ye S; Zhang X; Sun J; Li P; Yang T; Li F; Lin J; Zhang Z; Zhao Y; Li R; Guo X; Yao Q; Lu W; Qu S; Li H; Tan L; Wang W; Yao Y; Chen D; Li Y; Gao J; Hu W; Fei X; Wu T; Dong S; Jin W; Li C; Zhao D; Feng B; Zhao Y; Zhang Y; Li X; Chen L
    Nat Med; 2022 May; 28(5):974-981. PubMed ID: 35551292
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin.
    Jain A; Vispute A; Dange A; Naskar A; Mondal A; Vivekanand B; Sharma B; Varade D; Shukla D; Bhatia G; Chaudhari H; Ram Babu K; Gavali O; Sorate S; Bhanushali S; Kothari V; Khandelwal V; Sharma A; Pawar R; Mayabhate M; Shahavi V; Rajput A; Jaiswal M
    Diabetes Ther; 2024 Jan; 15(1):215-227. PubMed ID: 37957465
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
    Palmer AJ; Roze S; Lammert M; Valentine WJ; Minshall ME; Nicklasson L; Gall MA; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
    J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
    Kim HJ; Noh JH; Moon MK; Choi SH; Ko SH; Rhee EJ; Hur KY; Jeong IK
    J Diabetes Res; 2024; 2024():8915591. PubMed ID: 38223523
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
    Pan C; Li W; Zeng J; Li C; Yang J; Ji Q; Lu J; Lyu X; Li X; Qu S; Xu X; Xue Y; Li L; Jiang Z; Zheng B; Bu R; Han P; Liu Y; Liu J; Peng Y; Liu X; Liu Z; Yan L; Lei M; Li X; Song Q; Shi B; Gu W; Li Z
    Zhonghua Nei Ke Za Zhi; 2015 Nov; 54(11):949-53. PubMed ID: 26759214
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
    Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
    Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
    Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
    Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.
    Shestakova M; Kvasnikov B; Erina E; Isachenko E; Andreev A;
    BMJ Open Diabetes Res Care; 2023 Jun; 11(3):. PubMed ID: 37328272
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
    Mennecart M; Mondon K; Malherbe C; Constans T
    J Am Geriatr Soc; 2014 Dec; 62(12):2460-2. PubMed ID: 25516054
    [No Abstract]   [Full Text] [Related]  

  • 100. Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
    Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
    J Int Med Res; 2014 Oct; 42(5):1150-60. PubMed ID: 25015763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.